Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +3 moreLSD, psilocybin, mescaline, DOM, DOI, DOB show less
DOC
2,5-dimethoxy-4-chloroamphetamine
DOC (2,5-dimethoxy-4-chloroamphetamine) is a synthetic psychedelic of the phenethylamine class. It belongs to the DOx series — a family of halogenated compounds closely related to DOM, active at sub-milligram doses. It activates serotonin receptors in the brain, disrupting normal sensory filtering and producing its characteristic psychedelic effects.[1][2]
DOC (2,5-dimethoxy-4-chloroamphetamine) is a synthetic psychedelic of the phenethylamine class. It belongs to the DOx series — halogenated relatives of DOM — distinguished by sub-milligram potency and a duration reaching 24 hours. DOC is a partial agonist at 5-HT₂A serotonin receptors,[1] producing its effects by disrupting the brain's default filtering of sensory and cognitive input.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +3 moreLSD, psilocybin, mescaline, DOM, DOI, DOB show less
First synthesized in 1973 to study how halogen substitutions affect psychedelic potency,[3] DOC was later characterized by Alexander Shulgin in PiHKAL (1991).[4] Starting in 2004, it appeared in drug markets on blotter paper, frequently sold as LSD, leaving buyers unprepared for its far greater potency and longer duration.[5] The WHO recommended international scheduling in 2019, citing public health risk and no recognized therapeutic use.[5]
Subjective effects include geometric visual patterns, brightened colors, time alteration, accelerated thinking, and strong physical stimulation. The experience is electrically charged and bodily present — more stimulating than LSD, with a peak that plateaus for hours rather than tapering smoothly. Pronounced body load, vasoconstriction, and inability to sleep through the prolonged tail are characteristic unsought effects.
DOC produces no physical dependence, and the lethal dose in humans is unknown — two deaths appear in published case reports.[6][7] The main acute danger is a sympathomimetic crisis — seizures, dangerous overheating, and muscle breakdown — worsened by frequent misrepresentation as LSD.[5] No controlled human studies exist; current understanding comes from case reports, animal data, and analogy to related compounds.[5]
History[edit]
Discovery
DOC was first synthesized in 1973 to study how halogen substitutions at the 4-position of the ring affect psychedelic potency relative to DOM.[3] Alexander Shulgin self-tested it and documented it as entry #64 in PiHKAL (1991), establishing the active dose range and describing an archetypical psychedelic experience lasting 12–24 hours.[4]
Forensic Emergence
DOC appeared in European forensic notifications in 2004 and US seizures by 2006–2009, mostly as blotter paper sold as LSD.[5] Because DOC is far longer-lasting and more potent by weight, buyers using LSD doses were caught off guard.[8] The first death attributed solely to DOC was reported in 2014.[6]
Scheduling and Modern Status
The WHO recommended DOC be placed in Schedule I of the 1971 Convention on Psychotropic Substances in 2019, citing public health risk and no therapeutic value.[5] No clinical research has investigated DOC for any therapeutic purpose. It remains primarily a forensic concern and a pharmacological reference compound within the DOx series.[9]
The name DOC follows DOx series convention: DO for 2,5-dimethoxy, C for the 4-chloro substituent — parallel to DOM (methyl), DOI (iodo), and DOB (bromo). The compound has no widely recognized street names.
Chemistry[edit]
Structural Class
DOC belongs to the DOx series — a family of 2,5-dimethoxy-4-substituted phenylisopropylamine psychedelics that includes DOM, DOI, and DOB.[9] The distinguishing feature of DOC is a chlorine atom at the 4-position of the ring. The amphetamine backbone gives the DOx series greater metabolic stability and longer duration than the related 2C-x phenethylamines.
Molecular Properties
DOC's molecular formula is C₁₁H₁₆ClNO₂ (molecular weight 229.70 g/mol as free base; 266.17 g/mol as HCl salt).[1] The 2,5-dimethoxy pattern on the phenyl ring is shared across all DOx compounds and is essential for strong serotonin receptor binding.[5]
Pharmacology[edit]
Mechanism of Action
DOC is a partial agonist at serotonin receptors — primarily the 5-HT₂A type. Activating these receptors triggers a signaling cascade that raises cortical excitability and disrupts the brain's normal filtering of sensory information.[2] This is what drives the visual distortions and loosened thinking that define the DOC experience.
Despite sharing an amphetamine-like chemical backbone with conventional stimulants, DOC does not release dopamine, serotonin, or norepinephrine.[10] Its effects are entirely receptor-driven — confirmed in animal studies showing DOC behaves like serotonergic psychedelics, not stimulants.[5][11]
Pharmacokinetics
No controlled human pharmacokinetic studies exist for DOC — onset timing, half-life, and bioavailability are all unknown. The liver enzyme CYP2D6 handles most of DOC's breakdown, removing chemical groups to produce its main metabolites.[12] DOC weakly inhibits CYP2D6 in return, though this effect is unlikely to cause significant interactions at typical doses.[12]
Neuroscience[edit]
Where It Acts
DOC targets serotonin receptors concentrated in the deep layers of the cerebral cortex. When these fire, they amplify excitatory brain signaling and disrupt the system that normally filters sensory information before it reaches conscious awareness.[13] This is the leading explanation for DOC's visual distortions, sensory flooding, and loosened thinking.
DOC's potency at this pathway is confirmed by rodent behavioral studies[11] and its exceptionally strong receptor binding.[1] Whether DOC produces the same patterns of altered network activity seen with LSD and psilocybin has not been studied.
Theoretical Frameworks
Two ideas from psychedelic research offer context. The REBUS model proposes that serotonin receptor activation loosens the brain's predictive expectations, giving raw sensory experience more influence over conscious perception. The entropic brain hypothesis suggests psychedelics expand accessible brain states by increasing the randomness of spontaneous cortical activity. Neither has been directly tested in DOC studies.
Does DOC's amphetamine-based structure produce a different neural signature than tryptamine psychedelics like psilocybin, or lysergamides like LSD? How does its activity at two serotonin receptor subtypes shape the balance between visual effects and anxiety?
Subjective Effects[edit]
DOC delivers a long, electrically charged psychedelic experience. Intense visual distortion and cognitive loosening are shot through with persistent physical energy — a stimulation that keeps the body alert even as the mind ranges far. This gives DOC a driven, sometimes pressured character distinct from most other psychedelics.
Compared to LSD, DOC is more physically stimulating with a heavier body load, and its peak plateaus rather than tapering smoothly. Relative to psilocybin, it is more visually sharp, more energizing, and far longer-lasting — without the earthy sedation that typically characterizes tryptamine psychedelics.
First synthesized in 1973 during structure-activity research on DOM,[3] DOC was later characterized by Alexander Shulgin in PiHKAL (1991).[4] It surfaced in European forensic seizures starting in 2004, frequently misrepresented as LSD on blotter paper.[5] The WHO recommended international scheduling in 2019, citing public health risk and absence of therapeutic value.[5]
Subjective effects include geometric visual patterns, color enhancement, time alteration, thought acceleration, and physical stimulation. The experience unfolds as a sustained, electrically charged psychedelic arc — more stimulating and bodily present than LSD, with a peak that can occupy an entire waking day. Pronounced body load, vasoconstriction, and difficulty sleeping through the prolonged tail are characteristic unsought effects.
DOC produces no physical dependence, and the lethal dose in humans is unknown — two fatalities appear in the published literature.[6][7] The primary acute danger is a sympathomimetic crisis — seizures, dangerously elevated body temperature, and muscle breakdown — compounded by frequent misrepresentation as LSD, which leaves users unprepared for its potency and duration.[5] No controlled human studies have been conducted; the current understanding rests on case reports, animal pharmacology, and structural analogy to other DOx compounds.[5]
History[edit]
Discovery
DOC was first synthesized in 1973 by R. T. Coutts and J. L. Malicky at the University of Alberta, produced as part of a structure-activity study exploring how halogen substitution at the 4-position of the 2,5-dimethoxyphenyl ring affected psychoactive potency relative to DOM.[3] Alexander Shulgin later self-tested the compound and documented it as Entry #64 in PiHKAL (1991), establishing the active oral dose range of 1.5–3.0 mg and describing the effects as archetypical psychedelia across a 12–24-hour span.[4]
Forensic Emergence
DOC first appeared in European forensic notifications in 2004 and in US seizures during 2006–2009, primarily as powder, liquid, or blotter paper.[5] Its distribution on blotters — frequently misrepresented as LSD — became a persistent public health concern, because DOC's longer duration and different dose sensitivity caught users off guard.[8] The first published case of recreational DOC intoxication appeared in 2008,[9] and the first death attributed solely to DOC was reported in 2014.[6]
Scheduling and Modern Status
The WHO Expert Committee on Drug Dependence recommended Schedule I placement for DOC under the 1971 Convention on Psychotropic Substances at its 42nd meeting in 2019, citing public health risk, misrepresentation as LSD, and absence of therapeutic value.[5] No clinical research programs have investigated DOC for any therapeutic application. Its primary modern significance is as a pharmacological tool within the DOx series and as a forensic concern in unregulated drug markets.[10]
The name DOC follows DOx series convention: DO for 2,5-dimethoxy, C for the 4-chloro substituent — parallel to DOM (methyl), DOI (iodo), and DOB (bromo). The compound has no widely recognized street names.
Chemistry[edit]
Structural Class
DOC belongs to the DOx series of substituted amphetamines — a family of 2,5-dimethoxy-4-substituted phenylisopropylamine psychedelics. The parent scaffold is 2,5-dimethoxyamphetamine, with pharmacological activity determined by the 4-position substituent — in DOC's case, a chlorine atom.[10] The 2,5-dimethoxy pattern on the phenyl ring is shared across the DOx series (DOM, DOI, DOB) and is essential for strong serotonin receptor binding.
The amphetamine backbone (phenylisopropylamine) distinguishes DOx compounds from the structurally related 2C-x series (phenethylamines), providing greater metabolic stability and considerably longer duration of action.
Molecular Properties
| IUPAC name | 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine |
| Molecular formula | C₁₁H₁₆ClNO₂ |
| Molecular weight | 229.70 g/mol (free base); 266.17 g/mol (HCl salt) |
The molecule consists of a phenyl ring with methoxy groups at the 2- and 5-positions and a chlorine atom at the 4-position, connected to a propan-2-amine side chain.[1]
Stereochemistry
DOC has one asymmetric carbon at the alpha-position of the amphetamine side chain, producing (R)- and (S)-enantiomers. The compound is typically encountered as a racemic mixture.[5] No studies have characterized DOC's enantioselective pharmacology directly; by analogy with DOB, the R-enantiomer likely has higher serotonin receptor affinity.[10]inferred
Physical Properties
DOC hydrochloride is a white crystalline solid with a melting point of 187–194.5 °C depending on the synthetic route.[4] Published solubility data are not available.
Pharmacology[edit]
Mechanism of Action
DOC acts as a potent partial agonist at 5-HT₂A and 5-HT₂C serotonin receptors. Its psychedelic effects are driven primarily through 5-HT₂A receptor activation of the Gq/11 signaling pathway, which triggers a biochemical cascade that increases cortical excitability and disrupts normal sensory filtering.[2] The strength of this Gq signaling — not other downstream pathways — is the key predictor of psychedelic potency.[2]
At the cortical level, 5-HT₂A activation enhances excitatory signaling at deep-layer pyramidal neurons, a mechanism proposed to underlie the perceptual and cognitive alterations produced by this class of compounds.[11]
In animal studies, DOC produces behavioral markers consistent with 5-HT₂A agonism and generalizes to other serotonergic psychedelics (DOM, DMT) but not to methamphetamine, confirming a serotonergic rather than stimulant mechanism.[5][12]
Despite sharing an amphetamine backbone with conventional stimulants, DOC does not release or block reuptake of dopamine, serotonin, or norepinephrine.[13] Its effects are receptor-mediated, not transporter-mediated.
Pharmacokinetics
No controlled human pharmacokinetic studies exist for DOC. Bioavailability, time to peak plasma concentration, half-life, and protein binding are all unknown.
Metabolism occurs primarily through the liver enzyme CYP2D6, which removes the methoxy groups at the 2- and 5-positions to produce the main metabolites.[14] DOC also inhibits CYP2D6 competitively, though the inhibition is relatively weak compared to potent CYP2D6 inhibitors, making clinically significant drug interactions unlikely at typical doses.[14]
In forensic and clinical testing, the parent compound is more readily detected than its metabolites and serves as the preferred analytical target.[15]
Neuroscience[edit]
Where It Acts
DOC engages 5-HT₂A receptors concentrated on deep-layer pyramidal neurons of the cerebral cortex. Activation of these receptors amplifies excitatory glutamate signaling, disrupting the thalamocortical gating system that normally filters sensory information before it reaches conscious awareness.[11] This disruption is the leading explanation for the visual distortions, perceptual flooding, and cognitive loosening that define the DOC experience.
DOC's strong engagement of this pathway is confirmed by robust behavioral markers in rodent models[12] and its low-nanomolar receptor affinity.[1] Whether it produces the same patterns of default mode network dissolution and increased neural entropy observed with LSD and psilocybin has not been investigated.
Theoretical Frameworks
Two models from the broader psychedelic literature offer context. The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that 5-HT₂A activation loosens the brain's established expectations, allowing raw sensory data greater influence over conscious experience. The entropic brain hypothesis suggests psychedelics expand the range of accessible brain states by increasing the randomness of spontaneous cortical activity.
DOC's exceptionally long duration may extend these altered states well beyond what shorter-acting psychedelics produce, though no neuroimaging studies have tested this prediction. Whether DOC promotes structural brain changes through the same growth-factor pathways documented for other psychedelics also remains untested.
Does DOC's phenylalkylamine structure produce a distinct neural signature compared to tryptamine and lysergamide psychedelics? How does its nearly equal affinity for both 5-HT₂A and 5-HT₂C receptors shape the balance between perceptual effects and anxiety?
Subjective Effects[edit]
DOC delivers a psychedelic experience defined by sustained intensity and pronounced physical energy. At lower doses, perceptual sharpening and color saturation dominate, with cognitive effects remaining manageable. Higher doses bring deep visual distortion, thought fragmentation, and a mounting body stimulation that colors the entire experience with a characteristic electrical charge. Set and setting exert powerful influence across the dose range — the sheer length of the experience means that environmental comfort and psychological preparedness compound in importance as hours accumulate.
Compared to LSD, DOC is more physically stimulating and carries a heavier body load, with a peak that plateaus for longer rather than tapering smoothly. Relative to psilocybin, it is more energizing, more visually sharp, and far longer-lasting, lacking the earthy sedation that typically characterizes tryptamine psychedelics.
Effect Grid
At common doses (1.5–2.5 mg oral), the full psychedelic experience manifests: pronounced open- and closed-eye visuals with geometric patterning, color shifting, drifting and morphing of surfaces, and tracers. Time distortion becomes significant. Thought acceleration and conceptual thinking intensify, with experiences described as "archetypical" psychedelia comparable to LSD or psilocybin.
Physically, tachycardia, stimulation, jaw tension, temperature dysregulation, and appetite suppression are common. The experience spans 12–20 hours and demands a full-day commitment. Sleep is impossible for most of the duration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color alteration · Brightness alteration · Symmetrical texture repetition · Environmental patterning · Visual breathing · Depth perception distortion · Perspective distortion · Tracers · After-images · Visual diffraction · Music enhancement · Auditory enhancement · Dreaming suppression · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual morphing · Touch enhancement · Auditory distortion · Proprioceptive distortion · Spatial disorientation · Vestibular distortion · Visual haze / noise · Visual melting · Visual processing acceleration · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual acuity enhancement · Visual magnification · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · Object activation · Visual recursion · External hallucinations · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations
Visual breathing · Depth perception distortion · Perspective distortion · Tracers · After-images · Visual diffraction · Music enhancement · Auditory enhancement · Dreaming suppression · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual morphing · Touch enhancement · Auditory distortion · Proprioceptive distortion · Spatial disorientation · Vestibular distortion · Visual haze / noise · Visual melting · Visual processing acceleration · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual acuity enhancement · Visual magnification · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · Object activation · Visual recursion · External hallucinations · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations
Wakefulness · Appetite suppression · Restlessness · Insomnia · Spontaneous body sensations · Excessive sweating · Muscle tension · Dehydration sensation · Dry mouth · Body high · Heart rate perception changes · Physical fatigue · Body schema distortion · Nausea · Bodily pressures · Laughter fits · Motor control impairment · Tactile euphoria · Tingling / electric sensations · Trembling · Vibrations / buzzing · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Involuntary body movements · Diarrhea · Sexual arousal enhancement · Bodily lightness · Headache · Kundalini-like energy · Nasal congestion · Nystagmus (eye wobbles) · Increased urination · Salivation · Vomiting · Motor control enhancement · Abnormal heartbeat · Seizure threshold reduction · Tactile hallucination
Insomnia · Spontaneous body sensations · Excessive sweating · Muscle tension · Dehydration sensation · Dry mouth · Body high · Heart rate perception changes · Physical fatigue · Body schema distortion · Nausea · Bodily pressures · Laughter fits · Tactile euphoria · Tingling / electric sensations · Trembling · Vibrations / buzzing · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Involuntary body movements · Diarrhea · Sexual arousal enhancement · Bodily lightness · Headache · Kundalini-like energy · Nasal congestion · Nystagmus (eye wobbles) · Increased urination · Salivation · Vomiting · Motor control enhancement · Abnormal heartbeat · Seizure threshold reduction · Tactile hallucination
Novelty enhancement · Immersion enhancement · Thought connectivity · Aesthetic enhancement · Openness enhancement · Cognitive euphoria · Cognitive fatigue · Cognitive flexibility · Increased nature relatedness · Introspection enhancement · Multiple thought streams · Creativity enhancement · Cognitive impairment · Confusion · Thought disorganization · Analysis enhancement · Memory suppression · Focus suppression · Memory fragmentation · Thought loops · Humor enhancement · Information processing enhancement · Motivation enhancement · Cognitive dysphoria · Focus enhancement · Memory replays · Synchronicity · Language enhancement · Compulsive redosing urge · Amnesia · Delusions · Delirium
Aesthetic enhancement · Openness enhancement · Cognitive euphoria · Cognitive fatigue · Cognitive flexibility · Increased nature relatedness · Introspection enhancement · Multiple thought streams · Creativity enhancement · Cognitive impairment · Confusion · Thought disorganization · Analysis enhancement · Memory suppression · Focus suppression · Memory fragmentation · Thought loops · Humor enhancement · Information processing enhancement · Motivation enhancement · Cognitive dysphoria · Focus enhancement · Memory replays · Synchronicity · Language enhancement · Amnesia · Delusions · Delirium
Simultaneous emotions · Anxiety · Empathy enhancement · Catharsis · Irritability · Dysphoria · Mania
Catharsis · Irritability · Dysphoria
Social connection · Depersonalization · Trust enhancement · Communication enhancement · Ego inflation · Flow state · Sociability enhancement · Boundary dissolution · Identity alteration · Ego dissolution · Telepathic feelings
Ego inflation · Flow state · Sociability enhancement · Boundary dissolution · Identity alteration · Ego dissolution · Telepathic feelings
Time cessation
Non-dual awareness · Death-rebirth sequence · Entity contact · Transpersonal memory access
Recursive awareness
Timeline
First alerts appear 1–3 hours after oral ingestion: subtle mood shift, mild perceptual brightening, and a growing sense that something is changing. The slow onset is characteristic of the DOx class and may tempt impatient users to redose — a significant overdose risk.
Intensity builds steadily over 1–2 hours as visual and cognitive effects become unmistakable. Color enhancement, emerging geometric patterning, and increasing thought connectivity signal the approach of peak effects. Mild nausea, body tension, and rising heart rate are common.
The peak plateau spans 4–7 hours — a sustained maximum-intensity period that is unusually long among psychedelics. Pronounced visual distortions, profound time dilation, intense emotional amplification, and altered conceptual processing dominate. Physical stimulation and tachycardia persist throughout.
Effects remain clearly present but gradually diminish in intensity over 3–5 hours. Visual effects soften, cognitive alterations become more manageable, and a sense of returning normalcy alternates with residual waves of psychedelic perception. Physical stimulation persists.
A slow descent toward baseline over 2–4 hours. Residual visual and cognitive effects fade gradually. Fatigue from the extended experience becomes prominent.
A prolonged afterglow lasting 6–24 hours features residual mood changes, mild perceptual sensitivity, cognitive reflectiveness, and physical fatigue. Some users report difficulty sleeping even after subjective effects have resolved.
⚠ Do not drive or operate machinery until after a full night of restorative sleep following the experience, as residual impairment may persist well beyond perceived baseline return.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose has been established for DOC in humans, and the toxic dose is unknown.[5] Two deaths appear in published case reports — one in a 37-year-old male with no other substances besides caffeine,[6] and one in a young woman who experienced vomiting, seizures, and cardiac arrest.[7]
Acute Toxicity
Severe DOC poisoning presents as a sympathomimetic crisis: rapid heart rate, blood vessel constriction, seizures, dangerously elevated body temperature, and muscle breakdown. Symptoms can persist 24–33 hours.[5]
Heart and Circulation
DOC likely binds strongly to a serotonin receptor subtype linked to heart valve damage — the same mechanism implicated in damage seen with drugs like fenfluramine and MDMA.[14][15][16] No valve damage from DOC has been reported, but repeated heavy use carries a theoretical long-term cardiac risk.
Psychological Risks
DOC's 12–24-hour duration carries elevated risk of acute panic, anxiety spirals, and prolonged distress — especially in people who didn't know they were taking it.[8] Agitation and aggressive behavior have been documented in clinical cases.[17][5]
As a potent serotonin receptor activator, DOC carries the class-level risk of triggering latent psychotic disorders in predisposed individuals.inferred No data on persistent visual disturbances (HPPD) following DOC use have been published.
Tolerance and Dependence
Tolerance builds rapidly after a single dose, driven by downregulation.[2] Cross-tolerance with LSD, psilocybin, mescaline, and other DOx compounds is expected. Recovery timelines — approximately 3 days for tolerance to halve, 7 days for full reset — are inferred from class-level data, not DOC-specific studies.inferred
No dependence potential has been demonstrated in humans or animals.[5] Rapid tolerance functionally prevents compulsive redosing.
Drug Interactions
Tramadol: Classified as dangerous. Tramadol raises serotonin levels; combined with DOC's direct serotonin receptor activation, the two create additive risk of serotonin syndrome — dangerous overheating, agitation, and muscle rigidity.[18]
MAOIs: Monoamine oxidase inhibitors combined with serotonergic compounds risk serotonin syndrome. DOC acts through receptor binding rather than serotonin release, but the combination still introduces excess serotonergic stimulation.safety citation needed
SSRIs: Chronic SSRI use reduces the effects of serotonin-receptor psychedelics through receptor adaptation. A blunting of DOC's effects is expected by analogy with LSD.[19]
CYP2D6 substrates: DOC weakly inhibits the liver enzyme CYP2D6.[12] Interactions with medications processed by this enzyme are theoretically possible but unlikely at typical doses.
Contraindications
7 knownNo DOC-specific contraindication data exist. The following are inferred from its pharmacological profile:
- Psychotic disorders or family history of psychosis: Serotonin receptor activation may trigger or worsen psychotic episodes inferred
- Bipolar disorder: Risk of triggering manic or mixed episodes inferred
- Heart conditions: Rapid heart rate and vasoconstriction documented in case reports[5]
- Seizure disorders: Seizures documented in severe intoxication; pre-existing epilepsy may lower the threshold[5]
- Pregnancy: No reproductive safety data exist safety citation needed
- Lithium: The combination with serotonergic psychedelics is associated with seizures and unpredictable intensification safety citation needed
Harm Reduction[edit]
Forms & Identification
DOC's most dangerous real-world characteristic is its frequent sale as LSD on blotter paper.[8][5] Ehrlich's reagent is the essential screening tool: it reacts with indole compounds like LSD but not with DOC. A negative result on a blotter sold as LSD is a strong indicator of substitution.
Any blotter-form psychedelic that has not been reagent-tested could be a DOx compound, an NBOMe, or another long-acting substitute with a fundamentally different risk profile.
Guidelines
- Test before use. Reagent test any blotter or powder. Ehrlich's reagent (negative = not an indole compound) is the minimum screen. A positive Marquis result is expected for DOC.
- Start low. DOC is active at sub-milligram doses. Use a precision milligram scale — volumetric dosing for solutions. Never eyeball powder.
- Wait before redosing. Onset may take 1–3 hours. Redosing before full onset is the most common path to overdose with long-acting psychedelics.
- Prepare the environment. Secure a comfortable, safe space for 18–24 hours. Stock water, light food, and comfort items. Remove access to vehicles.
- Arrange a sitter. Brief them on the expected duration and the possibility that reassurance may be needed well into the experience.
- Eat lightly beforehand. A small meal 2–3 hours before dosing reduces nausea without substantially delaying onset.
- Hydrate steadily. Sympathomimetic stimulation increases fluid needs over a very long experience.
Set & Setting
DOC's duration — potentially exceeding 20 hours — makes preparation more consequential than with most psychedelics. A full day and the following night should be kept clear of obligations. What feels manageable at hour 2 may become overwhelming by hour 12.
A trusted, sober sitter is strongly recommended, ideally one familiar with the compound's extended timeline. Mental state at dosing matters: DOC amplifies existing mood, and a 20-hour amplification of anxiety is qualitatively different from a 6-hour one.
Aftercare & integration. The extended duration means even a positive experience may leave significant physical and psychological residue. Sleep is often disrupted for 24–36 hours after dosing; planning for recovery sleep the following day is essential.
Physical aftercare should prioritize hydration, light nutrition, and rest. Sympathomimetic stimulation can leave the body depleted — gentle movement is preferable to strenuous activity for at least 48 hours.
Psychological integration follows the same principles as other psychedelics: journaling soon after the experience, discussing the content with a trusted person, and allowing several days before drawing conclusions. If disturbing content emerged, or if anxiety or perceptual disturbances persist beyond a week, seek a mental health professional experienced in psychedelic-related concerns.
Recovery & Support
DOC does not produce physical dependence, and compulsive use is rare due to rapid tolerance. If DOC or other psychedelic use has become a recurring coping mechanism, or is causing distress, harm to relationships, or functional impairment, support is available.
The Fireside Project (62-FIRESIDE / 623-473-7433) provides a psychedelic peer support line. SAMHSA's National Helpline (1-800-662-4357) offers free referrals for substance use concerns. Integration therapists listed through the MAPS directory specialize in processing difficult psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an Emergency
Most DOC experiences involve discomfort but not danger. The following signs indicate a medical emergency requiring immediate help:
- Seizures or uncontrolled muscle rigidity
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Loss of consciousness or unresponsiveness
- Dark or absent urine (sign of muscle breakdown)
- Self-harm behavior or complete detachment from reality
Immediate Steps
- Call emergency services immediately if any of the above signs appear.
- Move the person to a cool, quiet environment. Remove excess clothing if they are overheating.
- Place an unconscious but breathing person in the recovery position (on their side).
- Do not restrain the person unless they are in immediate physical danger.
- Do not induce vomiting.
- Stay with them until help arrives. Monitor breathing and temperature.
What to Tell the Dispatcher
State that the person has taken a psychedelic stimulant (DOC or a DOx compound), the approximate amount and time of ingestion, and the symptoms being observed. In many jurisdictions, Good Samaritan laws protect people who call for help during a drug emergency — do not let fear of legal consequences delay the call.
Legal Status[edit]
DOC occupies a complex regulatory position internationally.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not formally scheduled (as of April 2026) | DEA proposed Schedule I placement in April 2022[20]} and December 2023[21]}. Administrative hearing stayed June 2024 pending US District Court decision. Potentially prosecutable under the Federal Analogue Act given structural similarity to DOM (Schedule I). |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the generic N-alkyl substituted amphetamine provision[17] |
| Germany | Anlage I (BtMG) | Most restrictive category; prohibits possession, trafficking, and manufacture except for authorized research |
| Canada | Schedule I (CDSA) | Scheduled as a hallucinogenic amphetamine analog |
| Australia | Restricted import (Customs Regulations Schedule 4) | Listed as an alkoxyamphetamine; additional state-level prohibition under poisons schedules |
| International (UN) | WHO ECDD recommended Schedule I (1971 Convention) | Recommendation made at 42nd ECDD meeting (2019);[5] formal CND scheduling action required for convention placement |
Analog Act Considerations
In the United States, DOC's structural similarity to DOM (Schedule I) makes it potentially prosecutable under the Federal Analogue Act even without formal scheduling[20]}. DEA rulemaking to formally schedule DOC has faced procedural delays since 2022, with an administrative hearing stayed in June 2024 pending judicial review[21]}.
Legal status varies by jurisdiction and changes frequently. This information reflects the state of law as of April 2026 and is not legal advice.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
No lethal dose has been established for DOC in any species, and the toxic dose in humans is unknown.[5]
Acute Toxicity
Two deaths have been attributed to DOC in the published literature. One involved a 37-year-old male with DOC confirmed in blood and no other psychoactive substances besides caffeine.[6] The second involved a young woman who experienced vomiting, seizures, and cardiac arrest.[7]
Severe DOC poisoning presents as a sympathomimetic crisis[5]:
- Cardiovascular: Rapid heart rate and vasoconstriction
- Neurological: Hallucinations, severe agitation, aggression, seizures
- Systemic: Muscle breakdown, dangerously elevated body temperature
- Duration: Symptoms may persist 24–33 hours
Heart and Circulation
DOC likely binds strongly to serotonin₂B receptors, based on the tight correlation between 5-HT₂A and 5-HT₂B affinity across DOx compounds.[16] 5-HT₂B activation is the established mechanism by which certain drugs cause heart valve damage, as demonstrated with fenfluramine and MDMA.[17][18] No cases of valve damage from DOC have been reported, but repeated high-dose use carries a theoretical long-term cardiac risk.
Psychological Risks
DOC's 12–24-hour duration is among the longest of any commonly encountered psychedelic. Extended psychedelic states carry elevated risk of acute panic, anxiety spirals, and distress — particularly for users who did not intend to take DOC or who believed they were taking LSD.[8] Agitation and aggressive behavior have been documented in clinical cases.[9][5]
No data on persistent perceptual changes (HPPD) following DOC use have been published. As a potent 5-HT₂A agonist, DOC carries the class-level risk of triggering latent psychotic disorders in predisposed individuals.inferred
Tolerance and Dependence
Tolerance develops rapidly after a single dose, driven by downregulation.[2] Cross-tolerance with other serotonergic psychedelics (LSD, psilocybin, mescaline, and other DOx compounds) is expected. Commonly cited recovery periods — approximately 3 days for tolerance half-life, 7 days for full reset — are inferred from class-level data, not DOC-specific studies.inferred
No dependence potential has been demonstrated in humans or animals.[5] Rapid tolerance functionally prevents compulsive redosing patterns.
Drug Interactions
Tramadol: Classified as dangerous. Tramadol's serotonin-boosting properties combined with DOC's direct serotonin receptor activation create additive risk of serotonin syndrome — a potentially life-threatening condition involving agitation, muscle rigidity, and dangerously elevated body temperature.[19]
MAOIs: Monoamine oxidase inhibitors combined with serotonergic compounds carry risk of serotonin syndrome. Although DOC acts through receptor binding rather than serotonin release, the combination introduces excess serotonergic stimulation.safety citation needed
SSRIs: Chronic SSRI use tends to reduce the subjective effects of 5-HT₂A agonist psychedelics through receptor adaptation, as demonstrated with LSD.[20] A similar blunting of DOC effects is expected.
CYP2D6 substrates: DOC weakly inhibits the CYP2D6 liver enzyme.[14] Interactions with medications processed by the same enzyme are theoretically possible but unlikely at typical doses.
Contraindications
7 knownNo DOC-specific contraindication data exist. The following are inferred from its pharmacological profile:
- Psychotic disorders or family history of psychosis: 5-HT₂A agonists may trigger or worsen psychotic episodes inferred
- Bipolar disorder: Risk of triggering manic or mixed episodes inferred
- Heart conditions: Rapid heart rate and blood vessel constriction documented in case reports pose risk to those with pre-existing cardiovascular disease[5]
- Seizure disorders: Seizures documented in severe intoxication; pre-existing epilepsy may lower the threshold[5]
- Pregnancy: No reproductive safety data exist; 5-HT₂A agonists are contraindicated during pregnancy as a precaution safety citation needed
- Lithium: The combination of lithium with serotonergic psychedelics is associated with seizures and unpredictable intensification of effects safety citation needed
Harm Reduction[edit]
Forms & Identification
DOC's most dangerous real-world characteristic is its frequent sale as LSD on blotter paper.[8][5] Reagent testing is the critical safeguard: Ehrlich's reagent reacts with indole-containing compounds like LSD but will not react with DOC, making it the essential screening tool for anyone acquiring psychedelics on blotter. A negative Ehrlich result on a blotter sold as LSD is a strong indicator of substitution.
The broader principle: any blotter-form psychedelic that has not been verified by reagent testing could be a DOx compound, an NBOMe, or another long-acting substitute with a fundamentally different risk profile.
Guidelines
- Test before use. Reagent test any blotter or powder. Ehrlich's reagent (negative = not an indole compound) is the minimum screen. A positive Marquis result is expected for DOC.
- Start low. DOC is active at sub-milligram doses. Use a precision milligram scale — volumetric dosing for solutions. Never eyeball powder.
- Wait before redosing. Onset may take 1–3 hours. Redosing before full onset is the most common path to overdose with long-acting psychedelics.
- Prepare the environment. Secure a comfortable, safe space for 18–24 hours. Stock water, light food, and comfort items. Remove access to vehicles.
- Arrange a sitter. Brief them on the expected duration and the possibility that reassurance may be needed well into the experience.
- Eat lightly beforehand. A small meal 2–3 hours before dosing reduces nausea without substantially delaying onset.
- Hydrate steadily. Sympathomimetic stimulation increases fluid needs over a very long experience.
Set & Setting
DOC's duration — potentially exceeding 20 hours from onset to baseline — makes preparation more consequential than with most psychedelics. A full day and the following night should be kept free of obligations. The setting must remain comfortable and safe for the entire duration; what feels manageable at hour 2 may become claustrophobic by hour 12.
A trusted, sober sitter is strongly recommended, ideally one who understands the compound's extended timeline and can provide reassurance during the long tail. Mental state at the time of dosing matters: DOC amplifies existing mood, and a 20-hour amplification of anxiety or distress is qualitatively different from a 6-hour one.
Aftercare & integration. The extended duration of DOC means that even a positive experience may leave significant physical and psychological residue. Sleep is often disrupted for 24–36 hours after dosing; planning for recovery sleep the following day is essential.
Physical aftercare should prioritize hydration, light nutrition, and rest. The sympathomimetic stimulation can leave the body depleted — gentle movement is preferable to strenuous activity for at least 48 hours.
Psychological integration follows the same principles as other psychedelics: journaling soon after the experience, discussing the content with a trusted person, and allowing several days before drawing conclusions. If disturbing content emerged during the experience, or if anxiety or perceptual disturbances persist beyond a week, seek a mental health professional experienced in psychedelic-related concerns.
Recovery & Support
DOC does not produce physical dependence, and compulsive use patterns are rare due to rapid tolerance. If DOC or other psychedelic use has become a recurring coping mechanism or is causing distress, harm to relationships, or functional impairment, support is available.
The Fireside Project (62-FIRESIDE / 623-473-7433) provides a psychedelic peer support line. SAMHSA's National Helpline (1-800-662-4357) offers free referrals for substance use concerns. Integration therapists listed through the MAPS directory specialize in processing difficult psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an Emergency
Most DOC experiences involve discomfort but not danger. The following signs indicate a medical emergency requiring immediate help:
- Seizures or uncontrolled muscle rigidity
- Body temperature hot to the touch through clothing
- Chest pain or irregular heartbeat
- Loss of consciousness or unresponsiveness
- Dark or absent urine (sign of muscle breakdown)
- Self-harm behavior or complete detachment from reality
Immediate Steps
- Call emergency services immediately if any of the above signs appear.
- Move the person to a cool, quiet environment. Remove excess clothing if they are overheating.
- Place an unconscious but breathing person in the recovery position (on their side).
- Do not restrain the person unless they are in immediate physical danger.
- Do not induce vomiting.
- Stay with them until help arrives. Monitor breathing and temperature.
What to Tell the Dispatcher
State that the person has taken a psychedelic stimulant (DOC or a DOx compound), the approximate amount and time of ingestion, and the symptoms you are observing. In many jurisdictions, Good Samaritan laws protect people who call for help during a drug emergency — do not let fear of legal consequences delay the call.
Legal Status[edit]
DOC occupies a complex regulatory position internationally. The WHO Expert Committee on Drug Dependence recommended Schedule I placement under the 1971 Convention on Psychotropic Substances at its 42nd meeting in 2019, citing public health risk and absence of therapeutic value.[5] Several national jurisdictions have independently scheduled DOC.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not formally scheduled (as of April 2026) | DEA proposed Schedule I placement in April 2022[21]} and December 2023[22]}. Administrative hearing stayed June 2024 pending US District Court decision. Potentially prosecutable under the Federal Analogue Act given structural similarity to DOM (Schedule I). |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the generic N-alkyl substituted amphetamine provision[9] |
| Germany | Anlage I (BtMG) | Most restrictive category; prohibits possession, trafficking, and manufacture except for authorized research |
| Canada | Schedule I (CDSA) | Scheduled as a hallucinogenic amphetamine analog |
| Australia | Restricted import (Customs Regulations Schedule 4) | Listed as an alkoxyamphetamine; additional state-level prohibition under poisons schedules |
| International (UN) | WHO ECDD recommended Schedule I (1971 Convention) | Recommendation made at 42nd ECDD meeting (2019);[5] formal CND scheduling action required for convention placement |
Analog Act Considerations
In the United States, DOC's structural relationship to DOM (Schedule I) makes it potentially prosecutable under the Federal Analogue Act (21 USC § 813) when intended for human consumption, even without formal scheduling. The DEA rulemaking process to formally schedule DOC[21]} has faced procedural delays, with an administrative hearing announced in April 2024 and subsequently stayed in June 2024 pending judicial review.
Frequently asked questions
What is DOC?
DOC is a substituted amphetamine psychedelic of the DOx series, active at sub-milligram doses with a duration of 12–24 hours. It acts as a 5-HT₂A/2C partial agonist, first synthesized in 1973 and characterized by Alexander Shulgin in PiHKAL (1991).
How long does DOC last?
Total duration by route of administration — Oral: 12 – 24 hours; Insufflated: Unknown. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for DOC?
Psychedex publishes a dosage table for DOC on this page covering these routes of administration: oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with DOC?
The highest-severity documented interactions for DOC: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is DOC addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for DOC: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, mescaline, DOM, DOI, DOB. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcWallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential — Nature Communications doi:10.1038/s41467-023-44016-1
- [3] ^abCoutts RT, Malicky JL (1973) The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM). — Canadian Journal of Chemistry doi:10.1139/v73-210
- [4]
- [5]
- [6] ^abcBarnett RY, Baker DD, Kelly NE, McGuire CE, Fassette TC, Gorniak JM (2014) A fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report. — Journal of Analytical Toxicology doi:10.1093/jat/bku087
references
- [1]
- [2] ^abcdWallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential — Nature Communications doi:10.1038/s41467-023-44016-1
- [3] ^abCoutts RT, Malicky JL (1973) The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM). — Canadian Journal of Chemistry doi:10.1139/v73-210
- [4]
- [5]
- [6] ^abcBarnett RY, Baker DD, Kelly NE, McGuire CE, Fassette TC, Gorniak JM (2014) A fatal intoxication of 2,5-dimethoxy-4-chloroamphetamine: a case report. — Journal of Analytical Toxicology doi:10.1093/jat/bku087